Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver

doi:10.1016/0006-2952(94)90223-2

Biochemical Pharmacology

Volume 48, Issue 1, 5 July 1994, Pages 59-64

https://doi.org/10.1016/0006-2952(94)90223-2 Get rights and content

Abstract

Expression of human cytochrome P450 (CYP) genes in human adult and fetal liver were studied using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. In adult liver mRNA of CYPs 1A1, 1A2, 2A6/2A7, 2B6/2B7, 2C8-19, 2D6, 2E1, 3A3/3A4 and 3A7 were detected while CYPs 2F1 and 4B1 were absent. In fetal liver mRNA of CYPs 2C8, 2D6, 3A3/3A4 and 3A7 were found but all other forms studied were undetectable. The results provide a comprehensive qualitative picture of the expression of CYP genes in families CYP1 through CYP4 in human adult and fetal liver.

References (42)

SJ Yaffe et al.
The presence of a monooxygenase system in human fetal liver microsomes
Life Sci
(1970)
O Pelkonen
Biotransformation of xenobiotics in the fetus
Pharmacol Ther
(1980)
M Kitada et al.
Purification and properties of cytochrome P-450 from homogenates of human fetal livers
Arch Biochem Biophys
(1985)
SA Wrighton et al.
Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family
Arch Biochem Biophys
(1989)
MG Ladona et al.
Monoclonal antibody directed detection of cytochrome P-450 (PCN) in human fetal liver
Biochem Pharmacol
(1988)
A Rane et al.
Comparison of human fetal hepatic and adrenal cytochrome P450 activities with some major gestational steroids and ethylmorphine as substrates
J Steroid Biochem Mol Biol
(1992)
B-J Song et al.
Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450s
J Biol Chem
(1986)
RW Bork et al.
Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity
J Biol Chem
(1989)
T Shimada et al.
Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism
J Biol Chem
(1986)
J Mäenpää et al.
Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse
Biochem Pharmacol
(1993)

SM Jones et al.

Expression of CYP2E1 during human development: methylation of the CYP2E1 gene in human fetal and adult liver samples

Biochem Pharmacol

(1992)

DR Nelson et al.

The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

DNA Cell Biol

(1993)

T Cresteil et al.

Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P450

Pediatr Pharmacol

(1982)

M Fasanen et al.

Characterization of human fetal hepatic cytochrome P-450-associated 7-ethoxyresorufin O-deethylase and aryl hydrocarbon hydroxylase activities by monoclonal antibodies

Dev Pharmacol Ther

(1987)

CJ Omiecinski et al.

Induction and developmental expression of cytochrome P4501A1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction

Cancer Res

(1990)

M Kitada et al.

Immunochemical characterization and toxicological significance of P-450HFLb purified from human fetal livers

Biochim Biophys Acta

(1992)

GI Murray et al.

Cytochrome P4501A expression in adult and fetal human liver

Carcinogenesis

(1992)

JE Hulla et al.

Developmental aspects of P450IIIA: prenatal activity and inducibility

Drug Metab Rev

(1989)

J-M Treluyer et al.

Expression of CYP2D6 in developing human liver

Eur J Biochem

(1991)

KE Noonan et al.

mRNA phenotyping by enzymatic amplification of randomly primed cDNA

Nucleic Acids Res

(1988)

J Devereux et al.

A comprehensive set of sequence analysis programs for VAX and convex systems

Nucleic Acids Res

(1984)

Cited by (195)

Application of reaction phenotyping to address pharmacokinetic variability in patient populations
2023, Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable-Case Studies for Critical Thinking
Understanding and anticipating pharmacokinetic variability in the clinic begins with an appropriate characterization of the elimination pathways of a potential drug as it progresses through preclinical studies. A major facet of this characterization includes in vitro reaction phenotyping studies, which are designed to estimate the specific contributions of individual enzymatic pathways to the clearance of a drug. This chapter will briefly cover sources of pharmacokinetic variability, specifically with regard to drug metabolizing enzymes and transporters. In vitro assays and subsequent in vivo studies used in reaction phenotyping approaches will be described, as will clinical assessments of metabolic pathways. Finally, key case examples where reaction phenotyping or polymorphic enzymes were found to play a key role in the resulting pharmacokinetic or pharmacodynamic outcomes in the clinic will be presented.
Could dehydroepiandrosterone (DHEA) be a novel target for depression?
2022, Journal of Affective Disorders Reports
Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics
2022, Advances in Pharmacology
Cytochrome P450 enzymes play an important role in the pharmacokinetics, efficacy, and toxicity of drugs. Age-dependent changes in P450 enzyme expression have been studied based on several detection systems, as well as by deconvolution of in vivo pharmacokinetic data observed in pediatric populations. The age-dependent changes in P450 enzyme expression can be important determinants of drug disposition in childhood, in addition to the changes in body size and the other physiological parameters, and effects of pharmacogenetics and disease on organ functions. As a tool incorporating drug-specific and body-specific factors, physiologically-based pharmacokinetic (PBPK) models have become increasingly used to characterize and explore mechanistic insights into drug disposition. Thus, PBPK models can be a bridge between findings from basic science and utilization in predictive science. Pediatric PBPK models incorporate additional system specific information on developmental physiology and ontogeny and have been used to predict pharmacokinetic parameters from preterm neonates onwards. These models have been advocated by regulatory authorities in order to support pediatric clinical trials.
The purpose of this chapter is to highlight accumulated knowledge and findings from basic research focusing on P450 enzymes, as well as the current status and future challenges of expanding the utilization of pediatric PBPK modeling.
Caffeine disrupts ataxia telangiectasia mutated gene-related pathways and exacerbates acetaminophen toxicity in human fetal immortalized hepatocytes
2021, Toxicology
Citation Excerpt :
The Affymetrix datasets identified numerous CYP mRNAs in hTERT-FH-B cells at levels corresponding to G6P or GGT mRNAs (Supplemental Table S1). Included are CYP mRNAs noted in fetal (e.g., 2C8, 2D6, 3A4), and adult liver (e.g., 1A1, 2A6, 2A7, 2B6, 2B7, 2C8, 2C9, 2C19, 2E1) (Hakkola et al., 1994), though the latter at much lower levels in hTERT-FH-B cells, as expected. The CYP1A1 metabolizing 7-ethoxyresorufin is expressed 2.5-fold less in hTERT-FH-B cells than adult hepatocytes.
Preterm infants are at greater risk for adverse drug effects due to hepatic immaturity. Multiple interventions during intensive care increases potential for drug interactions. In this setting, high-dose caffeine used for apnea in premature infants may increase acetaminophen toxicity by inhibiting ataxia telangiectasia mutated (ATM) gene activity during DNA damage response. To define caffeine and acetaminophen interaction, we modeled infantile prematurity in late-gestation fetal stage through human immortalized hepatocytes and liver organoids. The acute toxicity studies included assays for cell viability, mitochondrial dysfunction and ATM pathway-related DNA damage. Fetal cells expressed hepatobiliary properties, albeit with lower metabolic, synthetic and antioxidant functions than more mature hepatocytes. Acetaminophen in IC50 amount of 7.5 millimolar caused significant oxidative stress, mitochondrial membrane potential impairments, and DNA breaks requiring ATM-dependent repair. Caffeine markedly exacerbated acetaminophen toxicity by suppressing ATM activity in otherwise nontoxic 2.5 millimolar amount. Similarly, the specific ATM kinase antagonist, KU-60019, reproduced this deleterious interaction in 5 micromolar amount. Replicative stress from combined acetaminophen and caffeine toxicity depleted cells undergoing DNA synthesis in S phase and activated checkpoints for G0/G1 or G2/M restrictions. Synergistic caffeine and acetaminophen toxicity in liver organoids indicated these consequences should apply in vivo. The antioxidant, N-acetylcysteine, decreased oxidative damage, mitochondrial dysfunction and ATM pathway disruption to mitigate caffeine and acetaminophen toxicity. We concluded that hepatic DNA damage, mitochondrial impairment and growth-arrest after combined caffeine and acetaminophen toxicity will be harmful for premature infants. Whether caffeine and acetaminophen toxicity may alter outcomes in subsequently encountered hepatic disease needs consideration.
The Role of Biotransformation in Developmental Toxicity
2018, Comprehensive Toxicology: Third Edition
Biotransformation within both the mother and her developing embryo and fetus can play a variety of important roles in determining developmental toxicity or teratogenicity. Although the term “biotransformation” is typically associated with the metabolism of drugs and endogenous substrates, we have expanded this term to include reactions involved particularly in the formation and detoxification of reactive oxygen species, and the repair of oxidatively damaged DNA. The mother’s metabolism of a drug or environmental chemical (xenobiotic) can determine its elimination, thereby regulating the maternal plasma concentration of the xenobiotic, which in turn determines how much is available for transfer to the developing embryo or fetus. Once in the embryo or fetus, conceptal “bioactivating” pathways may convert a relatively nontoxic xenobiotic to a highly reactive and potentially toxic intermediary metabolite, such as an electrophilic or free radical intermediate, which can covalently (irreversibly) bind to or oxidatively damage embryonic cellular macromolecules such as DNA, RNA, proteins, and lipids, and/or directly alter cellular signal transduction. Oxidative damage and altered signal transduction are also caused by reactive oxygen species (ROS), which can be initiated by a drug-free radical or by drug-induced increases in endogenous pathways of ROS formation, such as ROS-producing NADPH oxidases (NOX). A teratogenic outcome will be dependent in part upon the mitigating protective effects of embryonic biotransforming pathways that detoxify either the xenobiotic reactive intermediate or the ROS initiated by some xenobiotics. A subsequent level of protection is afforded by embryonic pathways for the repair or removal of damaged cellular macromolecules. The regulatory effects of maternal xenobiotic metabolism and the balance among embryonic pathways of bioactivation and ROS formation, reactive intermediate and ROS detoxification, and repair of cellular macromolecules together determine the adverse developmental outcomes of xenobiotic exposure during pregnancy. Individual maternal and embryonic differences in these pathways of biotransformation, due to either genetic or environmental factors, can therefore constitute important determinants of risk.
The Developing Nervous System
2018, Comprehensive Toxicology: Third Edition
Because of the complexity and temporal features of the manifestations of the developing nervous system and/or developmental neurotoxicity, these areas of study may benefit greatly by monitoring alterations in gene and protein expression and cell signaling processes, and by using pharmacokinetic, behavioral, and imaging biomarkers. The developing nervous system possesses certain characteristics that may alter its susceptibility to toxicants as compared to the adult nervous system. Therefore, in the developing nervous system, where diverse cell types are differentiating from various primordial cells, the opportunity for differential toxicant effects is enhanced compared to mature, generally non-dividing cells of the adult nervous system.

View all citing articles on Scopus

View full text

Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver

Abstract

Life Sci

Pharmacol Ther

Arch Biochem Biophys

Arch Biochem Biophys

Biochem Pharmacol

J Steroid Biochem Mol Biol

J Biol Chem

J Biol Chem

J Biol Chem

Biochem Pharmacol

Biochem Pharmacol

The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

DNA Cell Biol

Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P450

Pediatr Pharmacol

Characterization of human fetal hepatic cytochrome P-450-associated 7-ethoxyresorufin O-deethylase and aryl hydrocarbon hydroxylase activities by monoclonal antibodies

Dev Pharmacol Ther

Induction and developmental expression of cytochrome P4501A1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction

Cancer Res

Immunochemical characterization and toxicological significance of P-450HFLb purified from human fetal livers

Biochim Biophys Acta

Cytochrome P4501A expression in adult and fetal human liver

Carcinogenesis

Developmental aspects of P450IIIA: prenatal activity and inducibility

Drug Metab Rev

Expression of CYP2D6 in developing human liver

Eur J Biochem

mRNA phenotyping by enzymatic amplification of randomly primed cDNA

Nucleic Acids Res

A comprehensive set of sequence analysis programs for VAX and convex systems

Nucleic Acids Res